Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy
Urine Total Adiponectin and Its Isoforms Concentration in Prediction of Percutaneous Coronary Interventions Contrast Induced Nephropathy
1 other identifier
observational
400
1 country
1
Brief Summary
The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of contrast induced nephropathy (CIN) in the patients undergoing PCI.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2010
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2010
CompletedFirst Submitted
Initial submission to the registry
June 10, 2011
CompletedFirst Posted
Study publicly available on registry
June 14, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2014
CompletedNovember 22, 2011
November 1, 2011
3 years
June 10, 2011
November 21, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
increase in SCr 0.5 mg/dL(44.2 mol/L) from baseline
samples will be collected at 24, 48 and 72 hours after PCI
3 days
Secondary Outcomes (1)
a 25% increase in SCr from baseline
3 days
Study Arms (1)
Patients underging PCI
Eligibility Criteria
This study enrolls a group of patients\> 18 who have ST elevation myocardial infarction (STEMI) undergoing primary PCI.
You may qualify if:
- All patients \> 18 of age who are undergoing elective PCI and are able to give informed consent are eligible for study.
You may not qualify if:
- The end-stage renal failure
- The patients who are relieving dialysis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Xijing Hospitallead
Study Sites (1)
Xijing Hospital
Xi'an, Shaanxi, 710032, China
Biospecimen
serum,urine
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 10, 2011
First Posted
June 14, 2011
Study Start
April 1, 2010
Primary Completion
April 1, 2013
Study Completion
December 1, 2014
Last Updated
November 22, 2011
Record last verified: 2011-11